Toll Free Phone:
1-866-892-2032; 
[email protected]
Servicing Healthcare Professionals and Companies
We Accept:
Free Shipping After: $1000
Never Overpay Again    |   5% First Order Discount   |   No Order Minimum   |   Free Replacement on Delays
Free Shipping After: $1000

HYALGAN® is an FDA-approved, avian-derived sodium hyaluronate viscosupplement from Fidia Pharma, indicated for intra-articular treatment of pain due to osteoarthritis of the knee in patients who have not responded adequately to conservative nonpharmacologic therapy and simple analgesics. Supplied as a 20 mg/mL, 2 mL prefilled syringe with an extensive evidence base from controlled clinical trials and an established Medicare billing pathway under J7321, HYALGAN® is a preferred choice by orthopedic and sports medicine practices managing knee OA. Licensed practitioners looking to buy HYALGAN® online, or to consolidate sourcing when they buy orthopedic injections, can access wholesale pricing through Medica Depot. Order HYALGAN® today or contact our team for procurement assistance.


FDA Approved

Showing the single result

HYALGAN 1SYRINGE ENGLISH 01
FDA Approved EU Approved

Buy HYALGAN® – Product Spotlight

HYALGAN® 20 mg/mL, 2 mL prefilled syringe is supplied as a single-use, sterile, ready-to-inject device for intra-articular knee injection [4]. A standard course is five weekly injections; some patients may benefit from three injections [1]. Clinics may individualize protocols within this 3–5-injection framework based on payer guidance, patient response, and published evidence on hyaluronic acid dose schedules in knee osteoarthritis [1][2].

Buy HYALGAN® injection online through Medica Depot with verified LOT numbers and consistent supply to support scheduled viscosupplementation programs. Clinics comparing where to buy HYALGAN® wholesale typically weigh the HYALGAN® injection price against their current distributor’s terms alongside pack format and delivery reliability.

About HYALGAN® and Fidia Pharma

HYALGAN® is one of the earliest sodium hyaluronate products developed specifically for intra-articular use in painful knee osteoarthritis, evaluated in multiple controlled clinical trials over several decades [1][2]. It is based on purified hyaluronan extracted from rooster combs and formulated to supplement degraded synovial fluid and help restore viscoelastic properties diminished in osteoarthritic joints [1][4].

HYALGAN® is produced by Fidia Farmaceutici (Fidia Pharma), an Italian company founded in 1946 in Abano Terme that specializes in hyaluronic acid-based medical devices [4]. Fidia’s hyaluronan portfolio extends well beyond HYALGAN®, including intra-articular products such as Hyalubrix and Sinovial in various international markets. That breadth reflects a long-standing institutional focus on HA science across orthopedics, wound care, ophthalmology, and aesthetics [4]. For procurement teams evaluating manufacturer depth, that HA experience across indications is relevant context when comparing HYALGAN® to products from less specialized manufacturers.

The Science of HYALGAN® — Sodium Hyaluronate and Intra‑Articular Treatment

HYALGAN® is a sterile, non-pyrogenic solution of purified sodium hyaluronate in buffered physiological sodium chloride, administered directly into the knee joint by intra-articular injection [1][4]. In knee osteoarthritis, endogenous hyaluronic acid becomes reduced in concentration and depolymerized, leaving synovial fluid less able to lubricate and cushion articular surfaces [2]. By supplementing the joint with exogenous hyaluronan, HYALGAN® aims to restore synovial fluid viscoelasticity, improving lubrication and shock absorption [1][2].

HYALGAN® ingredients consist of approximately 500–730 kDa sodium hyaluronate in a phosphate-buffered saline vehicle [2][4]. Because the sodium hyaluronate is avian-derived, all patients should be screened for hypersensitivity to avian proteins, feathers, or egg products before treatment [4]. While HYALGAN® is commonly discussed alongside pharmacologic therapies in osteoarthritis management, it is regulated as a medical device rather than a systemic pharmaceutical, reflecting its local mechanical and viscoelastic mechanism of action within the joint [4].

Treatment Areas and Patient Indications

HYALGAN® is FDA-approved for the treatment of pain from knee osteoarthritis in adults who have not responded adequately to nonpharmacologic therapy and simple analgesics [1][4]. Typical candidates include patients with radiographically confirmed knee OA whose symptoms remain inadequately controlled despite weight management, physical therapy, exercise, and oral analgesics. In routine practice, knee HYALGAN® injections are positioned within a multimodal, non-surgical OA management strategy.

The FDA-approved indication is specific to the knee joint. Sodium hyaluronate with comparable molecular weight characteristics has been studied in other joints, including the ankle and shoulder, where intra-articular hyaluronan has shown symptomatic benefit in selected patients [2]. Any application beyond the knee is considered off-label and should be guided by clinical judgment, local regulations, and applicable payer policies.

Administration — Dosing, Injection Protocol, and Aftercare

HYALGAN® is administered via intra-articular injection using aseptic technique. Any significant joint effusion should be aspirated with a separate sterile syringe before each injection to optimize distribution of the hyaluronan solution and reduce intra-articular pressure. A standard course is five weekly injections of the full 2 mL syringe contents (20 mg); some patients may benefit from three injections [1]. When both knees require treatment, a separate syringe is used for each joint. Repeat courses may be considered following an appropriate interval based on patient response and coverage criteria [3][4].

Common adverse events include transient pain, swelling, warmth, or effusion at the injection site, consistent with intra-articular sodium hyaluronate class effects and typically resolving within a few days [1]. Symptomatic improvement is typically gradual. Many patients notice relief developing across the injection course and in the months following the final dose, reflecting the viscoelastic mechanism of hyaluronan rather than the rapid onset seen with corticosteroid injections [1][3]. Because this is a temperature-sensitive injectable, shipping and storage conditions matter, and cold-chain integrity should be confirmed on receipt before the syringe is used.

HYALGAN® vs Competing Viscosupplements

The viscosupplementation landscape includes several hyaluronan products with varying molecular-weight profiles, origins, and injection schedules, creating a practical spectrum of HYALGAN® injection alternatives. HYALGAN® is frequently compared with ORTHOVISC®, EUFLEXXA®, MONOVISC®, SYNVISC®, and SUPARTZ®.

HYALGAN® vs ORTHOVISC®

HYALGAN® uses avian-derived sodium hyaluronate in a 3–5-injection series, while ORTHOVISC® is a non-avian product typically given over three to four injections. Source material is the primary clinical differentiator here. Practices that treat patients with avian sensitivity often buy ORTHOVISC® to keep a non-avian option on hand, whereas HYALGAN® tends to suit those that prioritize its longer clinical track record.

HYALGAN® vs EUFLEXXA®

HYALGAN® is avian-derived and typically administered over 3–5 injections, while EUFLEXXA® is produced via bacterial fermentation, which makes it non-avian, and is delivered as a three-injection course. Clinics whose formulary and billing workflows already center on the J7321 pathway lean toward HYALGAN®. Those managing avian-sensitive caseloads more often buy EUFLEXXA®, since the fermentation source removes the hypersensitivity concern.

HYALGAN® vs MONOVISC®

HYALGAN® follows a multi-injection course structure, while MONOVISC® is a single-injection viscosupplement. Practitioners who buy MONOVISC® alongside HYALGAN® can offer patients a choice between a staged weekly protocol and a single-visit treatment within the same injectable formulary. You can supply both products through Medica Depot, and buy HYALGAN® wholesale today.

HYALGAN® vs SYNVISC®

Both HYALGAN® and SYNVISC® are avian-derived, but HYALGAN® is a non-cross-linked sodium hyaluronate, while SYNVISC® is a cross-linked hylan G-F 20 formulation with a distinct rheologic profile and molecular structure. The cross-linking chemistry is the key technical differentiator for practitioners comparing the two avian-source products. Practitioners can buy SYNVISC® through Medica Depot to evaluate both formulations against their clinical and payer requirements.

HYALGAN® vs SUPARTZ®

HYALGAN® and SUPARTZ® are both avian-derived sodium hyaluronate viscosupplements, so the practical comparison centers on molecular weight, dosing schedule length, and coverage patterns rather than source material. The five-injection course of SUPARTZ® versus HYALGAN®’s 3–5-injection flexibility is often the deciding factor for practices comparing scheduling burden. They can buy SUPARTZ® to evaluate both against their patient volume and payer mix.

Check Regulatory Status, J‑Code, and Medicare Coverage, Before you Order HYALGAN® Online

HYALGAN® is FDA-approved as a medical device for the treatment of pain from knee osteoarthritis following failure of conservative therapies [4]. Product labeling emphasizes use in appropriately selected adult patients, consistent with common payer criteria for viscosupplementation [4].

Practitioners and billing teams searching for the HYALGAN® J code or J code for HYALGAN® are looking for HCPCS code J7321, defined as hyaluronan or derivative (HYALGAN®, Supartz, or Visco-3) for intra-articular injection, per dose. Claims pair J7321 with the appropriate major-joint injection code, and practitioners should confirm the current HYALGAN® injection CPT code combination under applicable CMS and commercial payer rules. Requirements to purchase HYALGAN® online can vary by jurisdiction, so licensed professionals should confirm what their regional and payer rules permit before ordering. Medicare coverage may apply when coverage and documentation criteria are met. This includes documented knee OA, failure of conservative therapy, and adherence to frequency limits, and local coverage determinations specify current documentation and interval requirements.

The depth of controlled clinical trial evidence supporting HYALGAN® is a practical asset for both practitioners and payers. The product has been evaluated in multiple randomized controlled trials and long-term studies, including foundational work by Moskowitz R and the HYALGAN® study group [1][2]. That literature documented the long-term efficacy and safety of intra-articular sodium hyaluronate in patients with osteoarthritis. This body of evidence is familiar to clinic billing teams and payers alike, reducing friction in prior authorization, coverage determinations, and claims processing in a way that newer viscosupplements with less extensive real-world data cannot replicate.

HYALGAN® Safety Profile — Side Effects and Contraindications

Most safety findings for HYALGAN® align with class effects for intra-articular hyaluronan products. Common adverse events, and key topics when patients ask about side effects of HYALGAN® injections, include:

  • Transient pain
  • Swelling
  • Warmth
  • Effusion in the treated joint

These events are usually mild to moderate and resolve within a few days with rest and conservative measures.

HYALGAN® is contraindicated in patients with known hypersensitivity to avian proteins, feathers, or egg products, and in patients with joint infections or skin diseases at the injection site [4]. Serious complications such as septic arthritis are rare but possible; strict aseptic technique and clear post-injection guidance are essential. Practitioners should review the full contraindication and precaution information in the current HYALGAN® IFU before administering.

Medica Depot supplies HYALGAN® 20 mg/mL in 2 mL prefilled syringes at competitive wholesale prices for licensed practitioners, with group-buy options, fast shipping, and verifiable LOT numbers to support efficient clinic inventory management. Practices can add HYALGAN® to their cart or contact our team for volume pricing arrangements. Practices that run aesthetic services alongside orthopedics can also buy dermal fillers through the same account, consolidating suppliers and paperwork. For clinics focused specifically on hyaluronic-acid products, the option to buy HA dermal fillers keeps the whole HA range, joint and facial, under one procurement relationship.

FAQs

Why is completing the full HYALGAN® injection series important?

HYALGAN® is designed to be administered as a multi-injection viscosupplementation course. Because symptom improvement may develop gradually, completing the prescribed series gives clinicians a better basis for assessing response rather than judging effectiveness after a single injection [1][2]. Order HYALGAN® online today, to stock the necessary supply for your clinic.

What should patients expect immediately after a HYALGAN® injection?

Temporary soreness, warmth, swelling, or discomfort around the treated knee may occur after intra-articular injection. Patients are generally advised to follow post-procedure instructions and avoid strenuous activity involving the knee for a short period after treatment [4].

Can HYALGAN® be considered after physical therapy or analgesics fail?

Yes. HYALGAN® is intended for patients with knee osteoarthritis who have not obtained adequate relief from conservative approaches such as non-pharmacologic therapy or simple analgesics. Treatment should still be individualized according to symptoms and clinical findings [1][2].

Why does allergy history matter before HYALGAN® treatment?

HYALGAN® is produced from avian-derived sodium hyaluronate. Clinicians should therefore review relevant allergy and sensitivity history and follow the contraindications and precautions in the current product labeling before administration [4]. Please check with your patient before you buy HYALGAN® online from Medica Depot.

How should clinicians evaluate whether HYALGAN® is working?

Pain severity, mobility, functional limitations, and patient-reported improvement can be documented throughout and after the injection series. Because response may continue to evolve after treatment, follow-up assessment is more informative than relying solely on immediate post-injection symptoms [1][3].

Can a patient receive another HYALGAN® series in the future?

Another course may be considered if symptoms recur and the patient previously experienced meaningful benefit. The decision should be based on clinical reassessment, current treatment guidance, and any payer-specific requirements for repeat viscosupplementation. It is important to talk about the HYALGAN® cost per injection and per treatment, so that patients can make an informed decision.

What should billing teams verify before a HYALGAN® claim is submitted?

Practices should confirm the current HCPCS product code, procedure code, billed units, medical-necessity documentation, treatment interval, and payer-specific authorization requirements. Checking these details before treatment can reduce avoidable reimbursement issues.

What should clinics check when they order HYALGAN® wholesale?

Clinics planning to order HYALGAN® wholesale through Medica Depot should consider anticipated treatment volume, pack quantities, expiration dates, LOT documentation, storage requirements, shipping conditions, and available group-buy pricing before finalizing inventory orders. We can offer the best HYALGAN® price on the market.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Altman RD, Moskowitz R, and the Hyalgan Study Group. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. The Journal of Rheumatology. 1998. https://pubmed.ncbi.nlm.nih.gov/9818665/

[2] Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan. International Journal of Clinical Practice. 2002. https://pubmed.ncbi.nlm.nih.gov/12510956/

[3] Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Seminars in Arthritis and Rheumatism. 2003. https://www.sciencedirect.com/science/article/abs/pii/S0049017202701212

[4] U.S. Food and Drug Administration. HYALGAN® PMA P950027 — Premarket Approval. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180040B.pdf

Written by the Medica Depot Editorial Staff

This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.

Choosing the right products starts with confidence in their authenticity. At Medica Depot, we prioritize genuine branded products, reliable sourcing, and quality you can trust. Explore our standards and learn more about how we ensure product authenticity.

Cart (0)

No products in the cart.

Continue shopping